Validation of the EORTC QLQ-C30 and QLQ-BN20, including WHO performance status interrater reliability, for evaluation of patients with intracranial meningiomas.

IF 2.5 Q2 CLINICAL NEUROLOGY
Neuro-oncology practice Pub Date : 2024-12-24 eCollection Date: 2025-06-01 DOI:10.1093/nop/npae125
Robert F Nilsson, Erik Ström, A Tommy Bergenheim, Rickard L Sjöberg, Peter Lindvall, Klas Holmgren
{"title":"Validation of the EORTC QLQ-C30 and QLQ-BN20, including WHO performance status interrater reliability, for evaluation of patients with intracranial meningiomas.","authors":"Robert F Nilsson, Erik Ström, A Tommy Bergenheim, Rickard L Sjöberg, Peter Lindvall, Klas Holmgren","doi":"10.1093/nop/npae125","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The EORTC questionnaires QLQ-C30 and QLQ-BN20 are commonly used to evaluate health-related quality of life in patients with meningiomas but have not undergone a disease-specific validation. The study aimed to address this issue and to determine the interrater reliability of WHO performance status (PS) assessments in these patients.</p><p><strong>Methods: </strong>This population-based study included prospectively enrolled intracranial meningiomas treated at Umeå University Hospital between October 14, 2010, and December 31, 2021, followed up until March 30, 2023. Patients were assessed by the EORTC questionnaires before and at 3 months after surgery. WHO PS categorized as high (0-1) or low (2-5) were evaluated for interrater reliability and used together with sick-leave status to determine the questionnaires' clinical validity. Remaining psychometric properties of the questionnaires were analyzed by conventional methods.</p><p><strong>Results: </strong>Of 513 eligible surgeries, 454 (88.5%) had responded to at least 1 questionnaire. WHO PS interrater agreement was 94.4%. The EORTC questionnaires' ability to distinguish between clinically distinct groups was high. Items correlated better with their own scale than others (most <i>r</i> > 0.70). Items measuring various aspects of the same construct showed good internal consistency (nearly all α > 0.70). Questionnaire responsiveness to symptom changes over time was acceptable. Several scales displayed floor and ceiling effects.</p><p><strong>Conclusions: </strong>The EORTC QLQ-C30 and QLQ-BN20 are overall valid instruments to evaluate patients with intracranial meningiomas but require awareness of certain limitations when specific functions and symptoms are addressed. WHO PS assessments can be applied to meningioma patients with high reproducibility between observers.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 3","pages":"467-477"},"PeriodicalIF":2.5000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12137214/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npae125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The EORTC questionnaires QLQ-C30 and QLQ-BN20 are commonly used to evaluate health-related quality of life in patients with meningiomas but have not undergone a disease-specific validation. The study aimed to address this issue and to determine the interrater reliability of WHO performance status (PS) assessments in these patients.

Methods: This population-based study included prospectively enrolled intracranial meningiomas treated at Umeå University Hospital between October 14, 2010, and December 31, 2021, followed up until March 30, 2023. Patients were assessed by the EORTC questionnaires before and at 3 months after surgery. WHO PS categorized as high (0-1) or low (2-5) were evaluated for interrater reliability and used together with sick-leave status to determine the questionnaires' clinical validity. Remaining psychometric properties of the questionnaires were analyzed by conventional methods.

Results: Of 513 eligible surgeries, 454 (88.5%) had responded to at least 1 questionnaire. WHO PS interrater agreement was 94.4%. The EORTC questionnaires' ability to distinguish between clinically distinct groups was high. Items correlated better with their own scale than others (most r > 0.70). Items measuring various aspects of the same construct showed good internal consistency (nearly all α > 0.70). Questionnaire responsiveness to symptom changes over time was acceptable. Several scales displayed floor and ceiling effects.

Conclusions: The EORTC QLQ-C30 and QLQ-BN20 are overall valid instruments to evaluate patients with intracranial meningiomas but require awareness of certain limitations when specific functions and symptoms are addressed. WHO PS assessments can be applied to meningioma patients with high reproducibility between observers.

EORTC QLQ-C30和QLQ-BN20评估颅内脑膜瘤患者的有效性验证,包括WHO性能状态互信度。
背景:EORTC问卷QLQ-C30和QLQ-BN20通常用于评估脑膜瘤患者的健康相关生活质量,但尚未经过疾病特异性验证。该研究旨在解决这一问题,并确定世卫组织在这些患者中的表现状态(PS)评估的相互可靠性。方法:这项基于人群的研究纳入了2010年10月14日至2021年12月31日期间在ume大学医院接受治疗的颅内脑膜瘤患者,随访至2023年3月30日。术前和术后3个月分别用EORTC问卷对患者进行评估。世卫组织PS分类为高(0-1)或低(2-5),对其进行互信度评估,并与病假状况一起用于确定问卷的临床效度。其余问卷的心理测量性质采用常规方法进行分析。结果:在513例符合条件的手术中,454例(88.5%)至少回答了1份问卷。WHO PS通俗者的一致性为94.4%。EORTC问卷区分临床不同组的能力很高。与其他项目相比,项目与自己的量表的相关性更好(大多数为0.70)。测量同一结构的不同方面的项目显示出良好的内部一致性(几乎所有α > 0.70)。问卷对症状随时间变化的反应是可以接受的。几个天平显示地板和天花板的效果。结论:EORTC QLQ-C30和QLQ-BN20总体上是评估颅内脑膜瘤患者的有效工具,但在处理特定功能和症状时需要注意一定的局限性。世卫组织PS评估可应用于脑膜瘤患者,在观察者之间具有高再现性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neuro-oncology practice
Neuro-oncology practice CLINICAL NEUROLOGY-
CiteScore
5.30
自引率
11.10%
发文量
92
期刊介绍: Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信